MBRX - モレキュリン・バイオテック （Moleculin Biotech Inc.） モレキュリン・バイオテックMBRXのチャート
MBRXの企業情報
| symbol | MBRx |
|---|---|
| 会社名 | Moleculin Biotech Inc （モレキュリン・バイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Moleculin Biotech Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin which it refers to as Annamycin an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress one involving a portfolio of small molecules which it refers to as the WP1066 Portfolio focused on the modulation of key oncogenic transcription factors involved in the progression of cancer and the WP1122 Portfolio a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma. As of April 3 2017 it had not generated any revenue from its operations. モレキュリン・バイオテックは米国のバイオ医薬品企業。臨床前と臨床段階において、がん治療薬の開発に焦点を当て、テキサス大学システムのMDアンダ―ソン・がんセンタ―とのライセンス契約に基づく。同社候補薬は「リボソ―ム型Annamycin」で、抵抗性急性脊髄性白血病の治療を目指す。本社はテキサス州ヒュ―ストン。 Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. |
| 本社所在地 | 5300 Memorial Drive Suite 950 Houston TX 77007 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 713-300-5160 |
| 設立年月日 | 42186 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.moleculin.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mbrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.86700 |
| 終値（lastsale） | 1.41 |
| 時価総額（marketcap） | 37874710.77 |
| 時価総額 | 時価総額（百万ドル） 32.50241 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 20.78041 |
| 当期純利益 | 当期純利益（百万ドル） -13.10300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Moleculin Biotech Inc revenues was not reported. Net loss increased 88% to $7.1M. Higher net loss reflects Research and development increase from $1.2M to $5.5M (expense) Gain from expiration of warrants decrease of 55% to $1M (income) General and administrative increase of 58% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.28. |
MBRXのテクニカル分析
MBRXのニュース
Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) 2023/03/01 13:45:00 PR Newswire
HOUSTON, March 1, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the first subject has been treated in…
Wittiest stocks:: 22nd Century Group, Inc. (NASDAQ:XXII -2.28%), Moleculin Biotech, Inc. (NASDAQ:MBRX 1.61%) 2023/02/25 13:11:30 Stock Equity
XXII has seen its SMA50 which is now -7.01%. In looking the SMA 200 we see that the stock has seen a -32.88%. MBRX has seen its SMA50 which is … The post Wittiest stocks:: 22nd Century Group, Inc. (NASDAQ:XXII -2.28%), Moleculin Biotech, Inc. (NASDAQ:MBRX 1.61%) appeared first on Stocks Equity .
Astonishing stocks: OncoCyte Corporation (NASDAQ:OCX -0.05%), Moleculin Biotech, Inc. (NASDAQ:MBRX 0.78%) 2023/02/18 12:29:19 Stock Equity
There are two main reasons why moving averages are useful in forex trading: First Reason is moving averages help traders define trend Second Reason is recognizes changes in trend. Now … The post Astonishing stocks: OncoCyte Corporation (NASDAQ:OCX -0.05%), Moleculin Biotech, Inc. (NASDAQ:MBRX 0.78%) appeared first on Stocks Equity .
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday 2023/02/06 12:37:23 InvestorPlace
Source: ventdusud / Shutterstock.com We’re starting off the week with an overview of the biggest pre-market stock movers for Monday! Moving stocks this morning are funding updates, earnings, and stock offerings. Let’s get into that news below! Pre-Market Stock Movers: 10 Top Gainers Secoo Holding (NASDAQ: SECO ) stock is rocketing more than 77% alongside heavy pre-market trading. Jiuzi Holdings (NASDAQ: JZXN ) shares are soaring over 45% as it also sees strong early morning trading on Monday. Kalera PLC (NASDAQ: KAL ) stock is surging more than 42%, which builds on Friday’s gains. Faraday Future (NASDAQ: FFIE ) shares are climbing over 34% after obtaining funding for electric vehicle (EV) production. Elys Game Technology (NASDAQ: ELYS ) stock is gaining more than 28% following an update on debentures and warrants . Catalent (NYSE: CTLT ) shares are increasing over 28% on reports Danaher (NYSE: DHR ) may want to acquire the company . T Stamp (NASDAQ: IDAI ) stock is heading more than 28% higher this morning.
Hot Stock in Focus: Acasti Pharma Inc. (NASDAQ:ACST -0.75%), Moleculin Biotech, Inc. (NASDAQ:MBRX) 2023/02/04 13:47:31 Stock Equity
Acasti Pharma Inc. (NASDAQ:ACST) with the stream of -0.75% also noticed, India Moleculin Biotech, Inc. (NASDAQ:MBRX) encountered a rapid change of 0.00% in the last hour of Friday’s trading session. … The post Hot Stock in Focus: Acasti Pharma Inc. (NASDAQ:ACST -0.75%), Moleculin Biotech, Inc. (NASDAQ:MBRX) appeared first on Stocks Equity .
Nasdaq Down 50 Points; Crude Oil Rises Over 1% 2022/11/29 19:26:33 Benzinga
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping more than 50 points on Tuesday. The Dow traded up 0.07% to 33,872.09 while the NASDAQ fell 0.51% to 10,993.66. The S&P 500 also fell, dropping, 0.11% to 3,959.43. Also check this: Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying Leading and Lagging Sectors Real estate shares rose by 1.1% on Tuesday. Leading the sector was strength from Offerpad Solutions Inc. (NYSE: OPAD ) and Newmark Group, Inc. (NASDAQ: NMRK ). In trading on Tuesday, utilities shares fell by 1.2%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose by 10.4% from a year ago in September. Equities Trading UP Apollo Endosurgery, Inc. (NASDAQ: APEN ) shares shot up 67% to $10.01 after the company announced it will be acquired by Boston Scientific for $10 per share in cash. Shares of Bilibili Inc. (NASDAQ: BILI ) got a boost, shooting 23% to $15.44 after the company reported better-than-expected Q3 adjusted EPS and sales results.
US Stocks Edge Higher Following Monday''s Sell-Off 2022/11/29 16:03:19 Benzinga
U.S. stocks traded slightly higher this morning, with the Dow Jones gaining more than 30 points on Tuesday. The blue-chip index dropped around 500 points on Monday. Following the market opening Tuesday, the Dow traded up 0.11% to 33,886.06 while the NASDAQ rose 0.32% to 11,084.58. The S&P 500 also rose, gaining, 0.26% to 3,974.32. Also check this: Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying Leading and Lagging Sectors Energy shares rose by 1.6% on Tuesday. Leading the sector was strength from Nine Energy Service, Inc. (NYSE: NINE ) and CONSOL Energy Inc. (NYSE: CEIX ). In trading on Tuesday, utilities shares fell by 0.8%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose by 10.4% from a year ago in September. Equities Trading UP Apollo Endosurgery, Inc. (NASDAQ: APEN ) shares shot up 65% to $9.90 after the company announced it will be acquired by Boston Scientific for $10 per share in cash. Shares of Bilibili Inc. (NASDAQ: BILI ) got a boost, shooting 24% to $15.57 after the company reported better-than-expected Q3 adjusted EPS and sales results.
Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying 2022/11/29 11:11:46 Benzinga
The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 Celularity The Trade: Celularity Inc. (NASDAQ: CELU ) CEO Robert Hariri bought a total of 40,000 shares at an average price of $1.74. To acquire these shares, it cost around $69.6 thousand. What’s Happening: The company recently posted a drop in quarterly earnings.. What Celularity Does: Celularity Inc is a … Full story available on Benzinga.com
Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript 2022/11/12 17:57:08 Seeking Alpha
Moleculin Biotech, Inc. (NASDAQ:NASDAQ:MBRX) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Walter Klemp – Chairman and Chief Executive Officer Jonathan…
Moleculin Biotech Earnings Miss, Revenue In line In Q3 By Investing.com 2022/11/11 07:51:00 Investing.com
Moleculin Biotech Earnings Miss, Revenue In line In Q3
MBRX stock gains after completing regulatory submissions for lead asset (NASDAQ:MBRX) 2022/09/07 11:46:29 Seeking Alpha
Seres Therapeutics, Inc. (MBRX), a biotech focused on microbiome therapeutics, added ~7% in the pre-market trading Wednesday after the company announced the completion of the…
Moleculin brain cancer therapy WP1122 gets FDA orphan drug status 2022/09/06 13:50:16 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) granted orphan drug designation to Moleculin Biotech''s (MBRX) WP1122 to treat Glioblastoma Multiforme ((GBM)), a type of brain…
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme 2022/09/06 12:45:00 PR Newswire
- Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug…